vimarsana.com

Page 6 - புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Proteomics analysis identifies potential drug targets for aggressive human cancers

 E-Mail Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets. They report in the journal Oncogene, the identification of proteomic signatures that are associated with clinical measures of aggressive disease for each of the seven cancer types studied. Some signatures were shared between different types of cancer and included cellular pathways of altered metabolism. Importantly, experimental results provided proof-of-concept that their proteomics analysis approach is a valuable strategy to identify potential therapeutic targets. There are two notable aspects of this study. One is that we explored the proteomic landscape of cancer looking for proteins that were expressed in association with aggressive forms of cancer, said co-corresponding author Dr. Chad Creighton, professor of medicine and co-director of Cancer Bioinformatics

Collagen plays protective role during pancreatic cancer development

Collagen plays protective role during pancreatic cancer development
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 News provided by Share this article DALLAS, March 3, 2021 /PRNewswire/  Dialectic Therapeutics, Inc. (Dialectic ®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Targeted Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.

North Texas Inno - Roundup: the top tech and startup funding rounds, M&As and investment activity for DFW in February

North Texas Inno - Roundup: the top tech and startup funding rounds, M&As and investment activity for DFW in February
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Targeting MAPK4: potential therapy for prostate cancer

Targeting MAPK4: potential therapy for prostate cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.